BCL2A1 and cancer: Concomitant expressions of IL-17A, with or without IFN-γ, pro-angiogenic VEGF, pro-survival BCL2A1 and suppressive IL-10 [39] or free radical peroxynitrite [40] may indicate that IL-17A strongly supports cancer development.